Success Metrics

Clinical Success Rate

80.0%

Based on 4 completed trials

Completion Rate

80%(4/5)

Active Trials

0(0%)

Results Posted

100%(4 trials)

Terminated

1(17%)

Phase Distribution

Ph phase_1

33%

Ph phase_2

50%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Phase 1Safety & dosage

2(40.0%)

Phase 2Efficacy & side effects

3(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

66.7%

4 of 6 finished

Non-Completion Rate

33.3%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(4)

Terminated(2)

Detailed Status

Completed4

Withdrawn1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

80.0%

Most Advanced

Phase 2

Trials by Phase

Phase 12 (40.0%)

Phase 23 (60.0%)

Trials by Status

completed467%

withdrawn117%

terminated117%

Recent Activity

0 active trials

Showing 5 of 6

completedphase_2

Clinical Trials (6)

Showing 6 of 6 trials

NCT04467840Phase 2

Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia

Completed

NCT04207255Phase 2

Addition of Opaganib to Androgen Antagonists in Patients With mCRPC

Completed

NCT04414618Phase 2

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

Completed

NCT02757326Phase 1

ABC294640 (Opaganib) in Refractory / Relapsed Multiple Myeloma

Terminated

NCT04502069Phase 1

Treatment of COVID-19 With Opaganib in Patients With Pneumonia Requiring Oxygen

Withdrawn

NCT04435106

Compassionate Use of Opaganib in Patients With Coronavirus Disease 2019 (COVID-19)

Completed

All 6 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 6